文档介绍：临床与病理杂志
2021, 41(7) h☀ps://
J Clin Pathol Res ancheng City Center Hospital, Xuancheng Anhui 242000;
3. Department of Cerebral Surgery, Xuancheng City Center Hospital, Xuancheng Anhui 242000, China)
Abstract Objective: To explore the application value of trastuzumab combined with pertuzumab in HER2 overexpression
收稿日期 (Date of reception)：2021–01–13
通信作者 (Corresponding author)：江卫兵，Email: *************@
万方数据1574 临床与病理杂志, 2021, 41(7) h☀ps://
of breast cancer (BC). Methods: A total of 46 BC patients with HER2 overexpression admi☀ed to our hospital
from January 2019 to December 2020 were included and randomly divided into trastuzumab group and
combination group, with 23 cases each. In addition to conventional treatment, the trastuzumab group was
given intravenous drip treatment with trastuzumab (8 mg/kg for the first dose and 6 mg/kg for the second
dose). In addition to trastuzumab, the combined group was treated with pertuzumab (840 mg for the ■rst dose,
420 mg for the second and subsequent doses). During the treatment, adverse reactions (ADR) of the patients were
recorded and graded.